2024
Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
Garcia-Gutierrez V, Huang F, Ashaye A, Dalal M, Laliman-Khara V, Breccia M, Rutherford M, Moradian H, Patos P, Jabbour E. Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison. Frontiers In Oncology 2024, 14: 1455378. PMID: 39634261, PMCID: PMC11615674, DOI: 10.3389/fonc.2024.1455378.Peer-Reviewed Original ResearchMatching-adjusted indirect comparisonChronic-phase chronic myeloid leukemiaChronic myeloid leukemiaT315I mutationCP-CMLMyeloid leukemiaTyrosine kinase inhibitor therapyIndirect comparisonsResponse rateBaseline responsesSecond-generation TKIsT315I mutation statusKinase inhibitor therapyThird-line therapyMedical literature databasesInhibitor therapyMutation subgroupsMutation statusPatient-level dataEfficacy outcomesBaseline characteristicsMMR rateProportion Z testClinical trialsCumulative rate
2023
Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study
Santini V, Zeidan A, Fenaux P, Madanat Y, Berry T, Feller F, Sun L, Xia Q, Wan Y, Huang F, Savona M, Platzbecker U. Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study. Blood 2023, 142: 4603. DOI: 10.1182/blood-2023-179378.Peer-Reviewed Original ResearchLower-risk myelodysplastic syndromesPlacebo groupTransfusion independenceTI ratesHot spot mutationsPoor prognosisMyelodysplastic syndromeRed blood cell transfusion independenceASXL1 mutationsErythropoiesis-stimulating agentsPhase 3 studyStudy of patientsTI responsesPresence of mutationsSpecific mutationsClinical responseStudy entryClinical efficacyClinical benefitPeripheral bloodMutation subgroupsDNMT3A mutationsEpigenetic modifiersPatientsRUNX1 mutations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply